Pregabalin Capsule
Product Images NDC 60760-729

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60760-729 (Pregabalin 60760 729 60)

Pregabalin Capsules 200 mg packaging label showing quantity of 60 capsules. The label includes NDC 60760-729-60, with manufacturing by Alkem Laboratories Ltd., Mumbai, India, and packaging by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label states storage instructions at controlled room temperature and includes barcode and lot/expiration placeholders.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula used to calculate creatinine clearance (CLCr), incorporating age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. This is a text panel containing pharmacokinetic or dosing-related calculation information.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

A bar graph depicting responder rates (%) for three groups: placebo (22.6%), 2.5 mg/kg/day dose (29.1%), and 10 mg/kg/day dose (40.6%). The horizontal axis lists treatment groups with sample sizes (N=93, 103, 96), and the vertical axis shows responder rate percentages.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

This chart shows responder rate percentages from two clinical studies (E1 and E3) measuring responses to different doses of pregabalin. The horizontal axis identifies treatment groups including placebo and various pregabalin doses (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) with dosing frequencies (BID, TID). The vertical axis shows responder rates from 0% to 60%. Bars indicate increasing responder rates with higher doses, with statistical significance noted versus placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph illustrating seizure reduction as median percent change from baseline against daily dose (mg/day) for Pregabalin. The graph compares four studies (E1 BID, E2 TID, E3 BID, E3 TID) with doses ranging from 0 (placebo) to 600 mg/day, showing significant seizure reduction increases at higher doses with associated p-values indicating statistical significance.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing trends of patient improvement over varying pain improvement percentages.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing percent improvement from baseline to Week 12 BOCF between Pregabalin and Placebo. The x-axis represents percent improvement, and the y-axis shows the percent of subjects improved, illustrating a higher improvement trend for Pregabalin compared to Placebo.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent of subjects improved over time from baseline to Week 16, showing Pregabalin versus Placebo. The x-axis represents the percent improved from baseline to Week 16 BOCF, while the y-axis shows the percent of subjects improved, with Pregabalin data depicted by a solid line and Placebo by a dashed line.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day to placebo, illustrating patient improvement curves over varying pain improvement percentages.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing percent improvement in patients' pain baseline over time for different doses of Pregabalin (75 mg, 150 mg, 300 mg twice a day) compared to placebo. The x-axis represents time in weeks, and the y-axis represents percent of patients improved.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

This line graph compares the percent improvement in pain from baseline to the percent of patients improved among three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percent of patients improved.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing the percent improvement in pain from baseline on the x-axis versus the percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo, with lines indicating their respective patient improvement percentages over a range from 0 to 100 percent.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line chart showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 300 mg, 450 mg, and 600 mg daily compared to placebo. The graph compares these four groups using different line styles over the range of pain improvement percentages.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier curve showing the estimated percentage of subjects without LTR (loss to response) over 180 days, comparing Pregabalin treatment versus Placebo. The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis represents time in days, from 0 to 180. Two survival curves are displayed, one solid line for Pregabalin and one dashed line for Placebo, indicating differences in outcomes over time.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure depicting the molecular formula of the active ingredient Pregabalin. The image shows the arrangement of atoms including carboxyl (CO2H) and amino (NH2) functional groups characteristic of Pregabalin's chemical formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.